""

Novo Nordisk, a Danish multinational pharmaceutical company, has reported compressing margins and collapsing guidance, confirming a sell thesis. The company's latest financial update reveals a decline in profit margins, primarily due to increased competition and pricing pressure in the diabetes and obesity treatment markets. As a result, Novo Nordisk has revised its full-year guidance, citing lower-than-expected sales and earnings. This development has significant implications for the company's stock performance and investor confidence. With a market capitalization of over $150 billion, Novo Nordisk is a major player in the global pharmaceutical industry. The company's struggles are attributed to the growing competition from biosimilar products and the impact of COVID-19 on healthcare systems. The revised guidance, announced on February 2023, reflects a 5-7% decline in sales and a 10-12% decrease in operating profit. This downturn has raised concerns among investors and analysts, highlighting the need for Novo Nordisk to reassess its strategy and adapt to the changing market landscape.